Tandem autotransplantation for the treatment of metastatic breast cancer

E. Randolph Broun, Raji Sridhara, George W. Sledge, David Loesch, Patricia H. Kneebone, Mark Hanna, Robert Hromas, Kenneth Cornetta, Lawrence H. Einhorn

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Purpose: To investigate the tolerability and impact on progression-free and overall survival of two consecutive cycles of high-dose chemotherapy (HDC) with autologous bona marrow transplantation (ABMT) in patients with previously untreated metastatic breast cancer. Patients and Methods: Twenty- eight patients received conventional-dose induction therapy (ITx) followed by a planned two cycles of HDC with ABMT. Median age was 45 years (range, 34 to 60 years). Sites of disease were bone (seven patients), visceral (three), soft tissue (11), multiple (six), and CNS (one). The ITx regimens of cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), methotrexate, fluorouracil, prednisone, and tamoxifen (CAMFTP) (three patients); fluorouracil, doxorubicin, and cyclophosphamide (FAC; 11 patients); cyclophosphamide, methotrexate, and fluorouracil (CMF; four patients); or doxorubicin or mitoxantrone/cyclophosphamide (10 patients) were given to maximum response (three to five cycles). HDC was cyclophosphamide 6 g/m2, carboplatin 2 g/m2, and etoposide 625 mg/m2 with ABMT. Results: Of 28 patients, 24 received two (86%) cycles of HDC. Four received only one cycle due to persistent toxicity from course 1 (one patient), no response to course 1 (two), and death on course 1 (one). Grade 3 to 4 nonhematologic toxicities included mucositis (in one or both cycles in 21 of 28 patients; 75%), diarrhea, nausea, and vomiting. Reversible peripheral neuropathy was seen in 15 of 28 patients and was severe in one. Documented infections were seen in 19 of 52 cycles. There was one transplant-related death. Six patients were converted from partial remission (PR) to complete remission (CR) with HDC; two of 24 patients (8%) were converted from PR to CR with the second cycle of HDC. Progression-free survival rate is nine of 28 patients (32%) with median follow-up of 23 months (range, 13 to 36+ months). Eighteen of 28 patients (64%) have progressed at 1 to 17 months from ABMT. Conclusion: Two cycles of HDC with ABMT was well tolerated with a high response rate in patients with metastatic breast cancer. The importance of the second cycle of HDC in this population is unclear.

Original languageEnglish (US)
Pages (from-to)2050-2055
Number of pages6
JournalJournal of Clinical Oncology
Volume13
Issue number8
DOIs
StatePublished - Aug 1995

Fingerprint

Autologous Transplantation
Breast Neoplasms
Drug Therapy
Cyclophosphamide
Therapeutics
Transplantation
Bone Marrow
Doxorubicin
Fluorouracil
Methotrexate
Disease-Free Survival
Mitoxantrone
Mucositis
Bone Diseases
Carboplatin
Peripheral Nervous System Diseases
Etoposide
Tamoxifen
Prednisone

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Broun, E. R., Sridhara, R., Sledge, G. W., Loesch, D., Kneebone, P. H., Hanna, M., ... Einhorn, L. H. (1995). Tandem autotransplantation for the treatment of metastatic breast cancer. Journal of Clinical Oncology, 13(8), 2050-2055. https://doi.org/10.1200/JCO.1995.13.8.2050

Tandem autotransplantation for the treatment of metastatic breast cancer. / Broun, E. Randolph; Sridhara, Raji; Sledge, George W.; Loesch, David; Kneebone, Patricia H.; Hanna, Mark; Hromas, Robert; Cornetta, Kenneth; Einhorn, Lawrence H.

In: Journal of Clinical Oncology, Vol. 13, No. 8, 08.1995, p. 2050-2055.

Research output: Contribution to journalArticle

Broun, ER, Sridhara, R, Sledge, GW, Loesch, D, Kneebone, PH, Hanna, M, Hromas, R, Cornetta, K & Einhorn, LH 1995, 'Tandem autotransplantation for the treatment of metastatic breast cancer', Journal of Clinical Oncology, vol. 13, no. 8, pp. 2050-2055. https://doi.org/10.1200/JCO.1995.13.8.2050
Broun ER, Sridhara R, Sledge GW, Loesch D, Kneebone PH, Hanna M et al. Tandem autotransplantation for the treatment of metastatic breast cancer. Journal of Clinical Oncology. 1995 Aug;13(8):2050-2055. https://doi.org/10.1200/JCO.1995.13.8.2050
Broun, E. Randolph ; Sridhara, Raji ; Sledge, George W. ; Loesch, David ; Kneebone, Patricia H. ; Hanna, Mark ; Hromas, Robert ; Cornetta, Kenneth ; Einhorn, Lawrence H. / Tandem autotransplantation for the treatment of metastatic breast cancer. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 8. pp. 2050-2055.
@article{f457b09639004f858b3633d7507395fd,
title = "Tandem autotransplantation for the treatment of metastatic breast cancer",
abstract = "Purpose: To investigate the tolerability and impact on progression-free and overall survival of two consecutive cycles of high-dose chemotherapy (HDC) with autologous bona marrow transplantation (ABMT) in patients with previously untreated metastatic breast cancer. Patients and Methods: Twenty- eight patients received conventional-dose induction therapy (ITx) followed by a planned two cycles of HDC with ABMT. Median age was 45 years (range, 34 to 60 years). Sites of disease were bone (seven patients), visceral (three), soft tissue (11), multiple (six), and CNS (one). The ITx regimens of cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), methotrexate, fluorouracil, prednisone, and tamoxifen (CAMFTP) (three patients); fluorouracil, doxorubicin, and cyclophosphamide (FAC; 11 patients); cyclophosphamide, methotrexate, and fluorouracil (CMF; four patients); or doxorubicin or mitoxantrone/cyclophosphamide (10 patients) were given to maximum response (three to five cycles). HDC was cyclophosphamide 6 g/m2, carboplatin 2 g/m2, and etoposide 625 mg/m2 with ABMT. Results: Of 28 patients, 24 received two (86{\%}) cycles of HDC. Four received only one cycle due to persistent toxicity from course 1 (one patient), no response to course 1 (two), and death on course 1 (one). Grade 3 to 4 nonhematologic toxicities included mucositis (in one or both cycles in 21 of 28 patients; 75{\%}), diarrhea, nausea, and vomiting. Reversible peripheral neuropathy was seen in 15 of 28 patients and was severe in one. Documented infections were seen in 19 of 52 cycles. There was one transplant-related death. Six patients were converted from partial remission (PR) to complete remission (CR) with HDC; two of 24 patients (8{\%}) were converted from PR to CR with the second cycle of HDC. Progression-free survival rate is nine of 28 patients (32{\%}) with median follow-up of 23 months (range, 13 to 36+ months). Eighteen of 28 patients (64{\%}) have progressed at 1 to 17 months from ABMT. Conclusion: Two cycles of HDC with ABMT was well tolerated with a high response rate in patients with metastatic breast cancer. The importance of the second cycle of HDC in this population is unclear.",
author = "Broun, {E. Randolph} and Raji Sridhara and Sledge, {George W.} and David Loesch and Kneebone, {Patricia H.} and Mark Hanna and Robert Hromas and Kenneth Cornetta and Einhorn, {Lawrence H.}",
year = "1995",
month = "8",
doi = "10.1200/JCO.1995.13.8.2050",
language = "English (US)",
volume = "13",
pages = "2050--2055",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Tandem autotransplantation for the treatment of metastatic breast cancer

AU - Broun, E. Randolph

AU - Sridhara, Raji

AU - Sledge, George W.

AU - Loesch, David

AU - Kneebone, Patricia H.

AU - Hanna, Mark

AU - Hromas, Robert

AU - Cornetta, Kenneth

AU - Einhorn, Lawrence H.

PY - 1995/8

Y1 - 1995/8

N2 - Purpose: To investigate the tolerability and impact on progression-free and overall survival of two consecutive cycles of high-dose chemotherapy (HDC) with autologous bona marrow transplantation (ABMT) in patients with previously untreated metastatic breast cancer. Patients and Methods: Twenty- eight patients received conventional-dose induction therapy (ITx) followed by a planned two cycles of HDC with ABMT. Median age was 45 years (range, 34 to 60 years). Sites of disease were bone (seven patients), visceral (three), soft tissue (11), multiple (six), and CNS (one). The ITx regimens of cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), methotrexate, fluorouracil, prednisone, and tamoxifen (CAMFTP) (three patients); fluorouracil, doxorubicin, and cyclophosphamide (FAC; 11 patients); cyclophosphamide, methotrexate, and fluorouracil (CMF; four patients); or doxorubicin or mitoxantrone/cyclophosphamide (10 patients) were given to maximum response (three to five cycles). HDC was cyclophosphamide 6 g/m2, carboplatin 2 g/m2, and etoposide 625 mg/m2 with ABMT. Results: Of 28 patients, 24 received two (86%) cycles of HDC. Four received only one cycle due to persistent toxicity from course 1 (one patient), no response to course 1 (two), and death on course 1 (one). Grade 3 to 4 nonhematologic toxicities included mucositis (in one or both cycles in 21 of 28 patients; 75%), diarrhea, nausea, and vomiting. Reversible peripheral neuropathy was seen in 15 of 28 patients and was severe in one. Documented infections were seen in 19 of 52 cycles. There was one transplant-related death. Six patients were converted from partial remission (PR) to complete remission (CR) with HDC; two of 24 patients (8%) were converted from PR to CR with the second cycle of HDC. Progression-free survival rate is nine of 28 patients (32%) with median follow-up of 23 months (range, 13 to 36+ months). Eighteen of 28 patients (64%) have progressed at 1 to 17 months from ABMT. Conclusion: Two cycles of HDC with ABMT was well tolerated with a high response rate in patients with metastatic breast cancer. The importance of the second cycle of HDC in this population is unclear.

AB - Purpose: To investigate the tolerability and impact on progression-free and overall survival of two consecutive cycles of high-dose chemotherapy (HDC) with autologous bona marrow transplantation (ABMT) in patients with previously untreated metastatic breast cancer. Patients and Methods: Twenty- eight patients received conventional-dose induction therapy (ITx) followed by a planned two cycles of HDC with ABMT. Median age was 45 years (range, 34 to 60 years). Sites of disease were bone (seven patients), visceral (three), soft tissue (11), multiple (six), and CNS (one). The ITx regimens of cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), methotrexate, fluorouracil, prednisone, and tamoxifen (CAMFTP) (three patients); fluorouracil, doxorubicin, and cyclophosphamide (FAC; 11 patients); cyclophosphamide, methotrexate, and fluorouracil (CMF; four patients); or doxorubicin or mitoxantrone/cyclophosphamide (10 patients) were given to maximum response (three to five cycles). HDC was cyclophosphamide 6 g/m2, carboplatin 2 g/m2, and etoposide 625 mg/m2 with ABMT. Results: Of 28 patients, 24 received two (86%) cycles of HDC. Four received only one cycle due to persistent toxicity from course 1 (one patient), no response to course 1 (two), and death on course 1 (one). Grade 3 to 4 nonhematologic toxicities included mucositis (in one or both cycles in 21 of 28 patients; 75%), diarrhea, nausea, and vomiting. Reversible peripheral neuropathy was seen in 15 of 28 patients and was severe in one. Documented infections were seen in 19 of 52 cycles. There was one transplant-related death. Six patients were converted from partial remission (PR) to complete remission (CR) with HDC; two of 24 patients (8%) were converted from PR to CR with the second cycle of HDC. Progression-free survival rate is nine of 28 patients (32%) with median follow-up of 23 months (range, 13 to 36+ months). Eighteen of 28 patients (64%) have progressed at 1 to 17 months from ABMT. Conclusion: Two cycles of HDC with ABMT was well tolerated with a high response rate in patients with metastatic breast cancer. The importance of the second cycle of HDC in this population is unclear.

UR - http://www.scopus.com/inward/record.url?scp=0029101450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029101450&partnerID=8YFLogxK

U2 - 10.1200/JCO.1995.13.8.2050

DO - 10.1200/JCO.1995.13.8.2050

M3 - Article

C2 - 7636548

AN - SCOPUS:0029101450

VL - 13

SP - 2050

EP - 2055

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -